5 EASY FACTS ABOUT CLINICAL BREAST CANCER DESCRIBED

Genomic sequencing analysis of 733 HER2-amplified primary and metastatic breast tumours disclosed substantial enrichment of mutations that activate RAS–MAPK signalling in Highly developed tumours dealt with with prior anti-HER2 therapies121. These mutations, together with NF1 and HER2 activating mutations, lead to resistance to tucatinib and nera